{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:52:14Z","timestamp":1791989534170,"version":"4.4.0"},"reference-count":143,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.expneurol.2017.08.014","type":"journal-article","created":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T04:47:17Z","timestamp":1504154837000},"page":"317-325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"PB","title":["The promise of signal transduction in genetically driven sarcomas of the nerve"],"prefix":"10.1016","volume":"299","author":[{"given":"AeRang","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7116-0605","authenticated-orcid":false,"given":"Christine A.","family":"Pratilas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"35","key":"10.1016\/j.expneurol.2017.08.014_bb0005","doi-asserted-by":"crossref","first-page":"57171","DOI":"10.18632\/oncotarget.11036","article-title":"Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors","volume":"7","author":"Ahsan","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.expneurol.2017.08.014_bb0010","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.9518","article-title":"Phase II trial of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumor (MPNST)","volume":"24","author":"Albritton","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.expneurol.2017.08.014_bb0015","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1535-7163.MCT-07-0518","article-title":"Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells","volume":"7","author":"Ambrosini","year":"2008","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.expneurol.2017.08.014_bb0020","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/his.13072","article-title":"Immunohistochemistry for trimethylated H3K27 in the diagnosis of malignant peripheral nerve sheath tumours","volume":"70","author":"Asano","year":"2017","journal-title":"Histopathology"},{"issue":"4","key":"10.1016\/j.expneurol.2017.08.014_bb0025","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1158\/0008-5472.CAN-09-2178","article-title":"The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo","volume":"70","author":"Banerjee","year":"2010","journal-title":"Cancer Res."},{"issue":"18","key":"10.1016\/j.expneurol.2017.08.014_bb0030","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1158\/1078-0432.CCR-06-0792","article-title":"The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1","volume":"12","author":"Barkan","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.expneurol.2017.08.014_bb0035","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/1535-7163.MCT-10-1087","article-title":"Phenotypic reversion of invasive neurofibromin-deficient schwannoma by FTS: Ras inhibition reduces BMP4\/Erk\/Smad signaling","volume":"10","author":"Barkan","year":"2011","journal-title":"Mol. Cancer Ther."},{"issue":"6371","key":"10.1016\/j.expneurol.2017.08.014_bb0040","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/356713a0","article-title":"Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients","volume":"356","author":"Basu","year":"1992","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.expneurol.2017.08.014_bb0045","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/ijc.24783","article-title":"Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft","volume":"126","author":"Bhola","year":"2010","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.expneurol.2017.08.014_bb0050","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/labinvest.3780293","article-title":"Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors","volume":"81","author":"Birindelli","year":"2001","journal-title":"Lab. Investig."},{"issue":"2","key":"10.1016\/j.expneurol.2017.08.014_bb0055","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/ng0296-144","article-title":"Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells","volume":"12","author":"Bollag","year":"1996","journal-title":"Nat. Genet."},{"issue":"11","key":"10.1016\/j.expneurol.2017.08.014_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047595","article-title":"Impaired Pten expression in human malignant peripheral nerve sheath tumours","volume":"7","author":"Bradtmoller","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.expneurol.2017.08.014_bb0065","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00401-013-1209-3","article-title":"Neuregulin-1 overexpression and Trp53 haploinsufficiency cooperatively promote de novo malignant peripheral nerve sheath tumor pathogenesis","volume":"127","author":"Brosius","year":"2014","journal-title":"Acta Neuropathol."},{"issue":"49","key":"10.1016\/j.expneurol.2017.08.014_bb0070","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1038\/onc.2013.506","article-title":"MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1","volume":"33","author":"Brundage","year":"2014","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.expneurol.2017.08.014_bb0075","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/NEN.0b013e3182859939","article-title":"Malignant peripheral nerve sheath tumor invasion requires aberrantly expressed EGF receptors and is variably enhanced by multiple EGF family ligands","volume":"72","author":"Byer","year":"2013","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"7","key":"10.1016\/j.expneurol.2017.08.014_bb0080","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Cancer Genome Atlas, N","year":"2015","journal-title":"Cell"},{"issue":"7216","key":"10.1016\/j.expneurol.2017.08.014_bb0085","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature07385","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"455","author":"Cancer Genome Atlas Research, N","year":"2008","journal-title":"Nature"},{"issue":"7353","key":"10.1016\/j.expneurol.2017.08.014_bb0090","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research, N","year":"2011","journal-title":"Nature"},{"issue":"7511","key":"10.1016\/j.expneurol.2017.08.014_bb0095","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","author":"Cancer Genome Atlas Research, N","year":"2014","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.expneurol.2017.08.014_bb0100","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00401-011-0928-6","article-title":"Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms","volume":"123","author":"Carroll","year":"2012","journal-title":"Acta Neuropathol."},{"issue":"3","key":"10.1016\/j.expneurol.2017.08.014_bb0105","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ajpath.2015.10.023","article-title":"The challenge of cancer genomics in rare nervous system neoplasms: malignant peripheral nerve sheath tumors as a paradigm for cross-species comparative oncogenomics","volume":"186","author":"Carroll","year":"2016","journal-title":"Am. J. Pathol."},{"issue":"5","key":"10.1016\/j.expneurol.2017.08.014_bb0110","doi-asserted-by":"crossref","first-page":"608","DOI":"10.15252\/emmm.201404430","article-title":"Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine","volume":"7","author":"Castellsague","year":"2015","journal-title":"EMBO Mol. Med."},{"issue":"5","key":"10.1016\/j.expneurol.2017.08.014_bb0115","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"issue":"13","key":"10.1016\/j.expneurol.2017.08.014_bb0120","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","article-title":"Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria","volume":"25","author":"Choi","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.expneurol.2017.08.014_bb0125","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1200\/JCO.2008.20.5054","article-title":"Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a Bayesian hierarchical statistical model","volume":"27","author":"Chugh","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.expneurol.2017.08.014_bb0130","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1126\/science.286.5447.2172","article-title":"Mouse models of tumor development in neurofibromatosis type I","volume":"286","author":"Cichowski","year":"1999","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.expneurol.2017.08.014_bb0135","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/modpathol.2016.45","article-title":"Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival","volume":"29","author":"Cleven","year":"2016","journal-title":"Mod. Pathol."},{"issue":"6","key":"10.1016\/j.expneurol.2017.08.014_bb0140","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ccr.2006.10.003","article-title":"A negative feedback signaling network underlies oncogene-induced senescence","volume":"10","author":"Courtois-Cox","year":"2006","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.expneurol.2017.08.014_bb0145","doi-asserted-by":"crossref","first-page":"599","DOI":"10.4161\/cbt.306","article-title":"Ras family signaling: therapeutic targeting","volume":"1","author":"Cox","year":"2002","journal-title":"Cancer Biol. Ther."},{"issue":"11","key":"10.1016\/j.expneurol.2017.08.014_bb0150","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: mission possible?","volume":"13","author":"Cox","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.expneurol.2017.08.014_bb0155","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1158\/1078-0432.CCR-14-3214","article-title":"Targeting RAS membrane association: back to the future for anti-RAS drug discovery?","volume":"21","author":"Cox","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.expneurol.2017.08.014_bb0160","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1158\/0008-5472.CAN-04-4058","article-title":"Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors","volume":"65","author":"Dasgupta","year":"2005","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.expneurol.2017.08.014_bb0165","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1086\/374821","article-title":"Elevated risk for MPNST in NF1 microdeletion patients","volume":"72","author":"De Raedt","year":"2003","journal-title":"Am. J. Hum. Genet."},{"issue":"3","key":"10.1016\/j.expneurol.2017.08.014_bb0170","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ccr.2011.08.014","article-title":"Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors","volume":"20","author":"De Raedt","year":"2011","journal-title":"Cancer Cell"},{"issue":"7521","key":"10.1016\/j.expneurol.2017.08.014_bb0175","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nature13561","article-title":"PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies","volume":"514","author":"De Raedt","year":"2014","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.expneurol.2017.08.014_bb0180","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0092-8674(92)90407-4","article-title":"Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis","volume":"69","author":"DeClue","year":"1992","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.expneurol.2017.08.014_bb0185","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1093\/annonc\/mdw281","article-title":"Phase II study of MLN8237 (Alisertib) in advanced\/metastatic sarcoma","volume":"27","author":"Dickson","year":"2016","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.expneurol.2017.08.014_bb0190","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1158\/1535-7163.MCT-13-0189","article-title":"NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition","volume":"12","author":"Dodd","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.expneurol.2017.08.014_bb0195","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1756-8722-6-93","article-title":"Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumor","volume":"6","author":"Du","year":"2013","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.expneurol.2017.08.014_bb0200","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1002\/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6","article-title":"Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases","volume":"57","author":"Ducatman","year":"1986","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.expneurol.2017.08.014_bb0205","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.expneurol.2017.08.014_bb0210","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1158\/1078-0432.CCR-12-1067","article-title":"Prognostic significance of AKT\/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors","volume":"19","author":"Endo","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.expneurol.2017.08.014_bb0215","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1158\/1078-0432.CCR-12-1067","article-title":"Prognostic significance of AKT\/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors","volume":"19","author":"Endo","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.expneurol.2017.08.014_bb0220","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/jmg.39.5.311","article-title":"Malignant peripheral nerve sheath tumours in neurofibromatosis 1","volume":"39","author":"Evans","year":"2002","journal-title":"J. Med. Genet."},{"issue":"5","key":"10.1016\/j.expneurol.2017.08.014_bb0225","first-page":"1573","article-title":"International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis","volume":"62","author":"Ferner","year":"2002","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.expneurol.2017.08.014_bb0230","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2230.1985.tb00559.x","article-title":"Sarcomas\u2013a clinicopathological guide with particular reference to cutaneous manifestation. II. Malignant nerve sheath tumour, leiomyosarcoma and rhabdomyosarcoma","volume":"10","author":"Fletcher","year":"1985","journal-title":"Clin. Exp. Dermatol."},{"issue":"2","key":"10.1016\/j.expneurol.2017.08.014_bb0235","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/(SICI)1096-8628(19970516)70:2<138::AID-AJMG7>3.0.CO;2-U","article-title":"Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients","volume":"70","author":"Friedman","year":"1997","journal-title":"Am. J. Med. Genet."},{"issue":"269","key":"10.1016\/j.expneurol.2017.08.014_bb0240","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"issue":"46","key":"10.1016\/j.expneurol.2017.08.014_bb0245","doi-asserted-by":"crossref","first-page":"19479","DOI":"10.1073\/pnas.0910398106","article-title":"PTEN dosage is essential for neurofibroma development and malignant transformation","volume":"106","author":"Gregorian","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.expneurol.2017.08.014_bb0250","first-page":"507","article-title":"Ras-GTP levels are elevated in human NF1 peripheral nerve tumors","volume":"12","author":"Guha","year":"1996","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.expneurol.2017.08.014_bb0255","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1158\/1535-7163.MCT-15-0365","article-title":"AZD2014, an inhibitor of mTORC1 and mTORC2, is highly effective in ER+ breast cancer when administered using intermittent or continuous schedules","volume":"14","author":"Guichard","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.expneurol.2017.08.014_bb0260","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/00008390-200404000-00014","article-title":"Cutaneous malignant melanoma and neurofibromatosis type 1","volume":"14","author":"Guillot","year":"2004","journal-title":"Melanoma Res."},{"issue":"17","key":"10.1016\/j.expneurol.2017.08.014_bb0265","doi-asserted-by":"crossref","first-page":"6804","DOI":"10.1158\/0008-5472.CAN-10-0409","article-title":"PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK\/ERK and mutant KRAS signaling","volume":"70","author":"Halilovic","year":"2010","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.expneurol.2017.08.014_bb0270","first-page":"481","article-title":"Identification of neurofibromatosis type I gene product as an insoluble GTPase-activating protein toward ras p21","volume":"7","author":"Hattori","year":"1992","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.expneurol.2017.08.014_bb0275","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/neuonc\/not248","article-title":"BRAFV600E mutation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors","volume":"16","author":"Hirbe","year":"2014","journal-title":"Neuro-Oncology"},{"issue":"18","key":"10.1016\/j.expneurol.2017.08.014_bb0280","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1158\/1078-0432.CCR-14-3049","article-title":"Whole exome sequencing reveals the order of genetic changes during malignant transformation and metastasis in a single patient with NF1-plexiform neurofibroma","volume":"21","author":"Hirbe","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.expneurol.2017.08.014_bb0285","doi-asserted-by":"crossref","first-page":"7403","DOI":"10.18632\/oncotarget.7232","article-title":"Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to promote malignant peripheral nerve sheath tumor formation","volume":"7","author":"Hirbe","year":"2016","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.expneurol.2017.08.014_bb0290","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1593\/neo.07304","article-title":"MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors","volume":"9","author":"Holtkamp","year":"2007","journal-title":"Neoplasia"},{"issue":"6","key":"10.1016\/j.expneurol.2017.08.014_bb0295","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1215\/15228517-2008-053","article-title":"EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy","volume":"10","author":"Holtkamp","year":"2008","journal-title":"Neuro-Oncology"},{"issue":"19","key":"10.1016\/j.expneurol.2017.08.014_bb0300","doi-asserted-by":"crossref","first-page":"7269","DOI":"10.1523\/JNEUROSCI.23-19-07269.2003","article-title":"Hypertrophic neuropathies and malignant peripheral nerve sheath tumors in transgenic mice overexpressing glial growth factor beta3 in myelinating Schwann cells","volume":"23","author":"Huijbregts","year":"2003","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.expneurol.2017.08.014_bb0305","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/PL00012105","article-title":"Allelic loss of the NF1 gene in anal malignant melanoma in a patient with neurofibromatosis type 1","volume":"6","author":"Ishii","year":"2001","journal-title":"Int. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.expneurol.2017.08.014_bb0310","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1172\/JCI60578","article-title":"MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors","volume":"123","author":"Jessen","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.expneurol.2017.08.014_bb0315","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11060-013-1295-z","article-title":"Efficacy and selectivity of nilotinib on NF1-associated tumors in vitro","volume":"116","author":"Jiang","year":"2014","journal-title":"J. Neuro-Oncol."},{"issue":"24","key":"10.1016\/j.expneurol.2017.08.014_bb0320","doi-asserted-by":"crossref","first-page":"8573","DOI":"10.1073\/pnas.0503224102","article-title":"The NF1 tumor suppressor critically regulates TSC2 and mTOR","volume":"102","author":"Johannessen","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.expneurol.2017.08.014_bb0325","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cub.2007.11.066","article-title":"TORC1 is essential for NF1-associated malignancies","volume":"18","author":"Johannessen","year":"2008","journal-title":"Curr. Biol."},{"issue":"5","key":"10.1016\/j.expneurol.2017.08.014_bb0330","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/1535-7163.MCT-07-2335","article-title":"Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors","volume":"7","author":"Johansson","year":"2008","journal-title":"Mol. Cancer Ther."},{"issue":"10","key":"10.1016\/j.expneurol.2017.08.014_bb0335","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1054\/bjoc.2001.1796","article-title":"Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials","volume":"84","author":"Johnson","year":"2001","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.expneurol.2017.08.014_bb0340","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1200\/JCO.20.3.791","article-title":"Postoperative nomogram for 12-year sarcoma-specific death","volume":"20","author":"Kattan","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.expneurol.2017.08.014_bb0345","doi-asserted-by":"crossref","DOI":"10.1017\/S1462399409001227","article-title":"Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways","volume":"11","author":"Katz","year":"2009","journal-title":"Expert Rev. Mol. Med."},{"issue":"3","key":"10.1016\/j.expneurol.2017.08.014_bb0350","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.ajpath.2012.11.017","article-title":"Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis","volume":"182","author":"Kazmi","year":"2013","journal-title":"Am. J. Pathol."},{"issue":"33","key":"10.1016\/j.expneurol.2017.08.014_bb0355","doi-asserted-by":"crossref","first-page":"53191","DOI":"10.18632\/oncotarget.10668","article-title":"CK2 blockade causes MPNST cell apoptosis and promotes degradation of beta-catenin","volume":"7","author":"Kendall","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.expneurol.2017.08.014_bb0360","doi-asserted-by":"crossref","first-page":"620834","DOI":"10.1155\/2012\/620834","article-title":"Conditional inactivation of Pten with EGFR overexpression in Schwann cells models sporadic MPNST","volume":"2012","author":"Keng","year":"2012","journal-title":"Sarcoma"},{"issue":"13","key":"10.1016\/j.expneurol.2017.08.014_bb0365","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1158\/0008-5472.CAN-11-4092","article-title":"PTEN and NF1 inactivation in Schwann cells produces a severe phenotype in the peripheral nervous system that promotes the development and malignant progression of peripheral nerve sheath tumors","volume":"72","author":"Keng","year":"2012","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.expneurol.2017.08.014_bb0370","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/onc.2016.269","article-title":"Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors","volume":"36","author":"Ki","year":"2017","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.expneurol.2017.08.014_bb0375","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1357-4310(00)01789-5","article-title":"RAS inhibitors: potential for cancer therapeutics","volume":"6","author":"Kloog","year":"2000","journal-title":"Mol. Med. Today"},{"issue":"1","key":"10.1016\/j.expneurol.2017.08.014_bb0380","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0165-4608(99)00006-0","article-title":"Allelic loss of the NF1 gene in NF1-associated plexiform neurofibromas","volume":"113","author":"Kluwe","year":"1999","journal-title":"Cancer Genet. Cytogenet."},{"issue":"6","key":"10.1016\/j.expneurol.2017.08.014_bb0385","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0002-9440(10)65508-3","article-title":"Expression of p27(kip) and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: the emerging role of p27(kip) in malignant transformation of neurofibromas","volume":"155","author":"Kourea","year":"1999","journal-title":"Am. J. Pathol."},{"issue":"6","key":"10.1016\/j.expneurol.2017.08.014_bb0390","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0002-9440(10)65504-6","article-title":"Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas","volume":"155","author":"Kourea","year":"1999","journal-title":"Am. J. Pathol."},{"issue":"9","key":"10.1016\/j.expneurol.2017.08.014_bb0395","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/ng.3361","article-title":"Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas","volume":"47","author":"Krauthammer","year":"2015","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/j.expneurol.2017.08.014_bb0400","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1210\/jc.2007-2825","article-title":"BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines","volume":"93","author":"Leboeuf","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"10.1016\/j.expneurol.2017.08.014_bb0405","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/ng.3095","article-title":"PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors","volume":"46","author":"Lee","year":"2014","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.expneurol.2017.08.014_bb0410","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/gcc.2870100405","article-title":"TP53 mutations are frequent in malignant NF1 tumors","volume":"10","author":"Legius","year":"1994","journal-title":"Genes Chromosomes Cancer"},{"issue":"15","key":"10.1016\/j.expneurol.2017.08.014_bb0415","first-page":"4507","article-title":"Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model","volume":"62","author":"Li","year":"2002","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.expneurol.2017.08.014_bb0420","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1158\/0008-5472.CAN-10-2799","article-title":"Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors","volume":"71","author":"Lopez","year":"2011","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.expneurol.2017.08.014_bb0425","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1158\/1078-0432.CCR-13-0780","article-title":"The activation of the WNT signaling pathway is a Hallmark in neurofibromatosis type 1 tumorigenesis","volume":"20","author":"Luscan","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.expneurol.2017.08.014_bb0430","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/2159-8290.CD-12-0313","article-title":"Elucidating distinct roles for NF1 in melanomagenesis","volume":"3","author":"Maertens","year":"2013","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.expneurol.2017.08.014_bb0435","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/sj.mt.6300038","article-title":"Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model","volume":"15","author":"Mahller","year":"2007","journal-title":"Mol. Ther."},{"issue":"19","key":"10.1016\/j.expneurol.2017.08.014_bb0440","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1200\/JCO.2008.20.4495","article-title":"Phase II study of sorafenib in patients with metastatic or recurrent sarcomas","volume":"27","author":"Maki","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.expneurol.2017.08.014_bb0445","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1158\/2159-8290.CD-14-0159","article-title":"Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers","volume":"4","author":"Malone","year":"2014","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.expneurol.2017.08.014_bb0450","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1158\/1078-0432.CCR-07-1305","article-title":"High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization","volume":"14","author":"Mantripragada","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.expneurol.2017.08.014_bb0455","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1124\/jpet.105.091454","article-title":"The mitogen-activated protein kinase\/extracellular signal-regulated kinase kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines","volume":"316","author":"Mattingly","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"6","key":"10.1016\/j.expneurol.2017.08.014_bb0460","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/s00428-001-0550-4","article-title":"Immunohistochemical and molecular analysis of p53, RB, and PTEN in malignant peripheral nerve sheath tumors","volume":"440","author":"Mawrin","year":"2002","journal-title":"Virchows Arch."},{"issue":"7","key":"10.1016\/j.expneurol.2017.08.014_bb0465","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/jmg.2006.048140","article-title":"Further evidence of the increased risk for malignant peripheral nerve sheath tumour from a Scottish cohort of patients with neurofibromatosis type 1","volume":"44","author":"McCaughan","year":"2007","journal-title":"J. Med. Genet."},{"issue":"12","key":"10.1016\/j.expneurol.2017.08.014_bb0470","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/cam4.551","article-title":"Whole-exome sequencing of breast cancer, malignant peripheral nerve sheath tumor and neurofibroma from a patient with neurofibromatosis type 1","volume":"4","author":"McPherson","year":"2015","journal-title":"Cancer Med."},{"issue":"14","key":"10.1016\/j.expneurol.2017.08.014_bb0475","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1073\/pnas.87.14.5435","article-title":"Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis","volume":"87","author":"Menon","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.expneurol.2017.08.014_bb0480","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.expneurol.2017.08.014_bb0485","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.cell.2013.01.053","article-title":"CXCR4\/CXCL12 mediate autocrine cell-cycle progression in NF1-associated malignant peripheral nerve sheath tumors","volume":"152","author":"Mo","year":"2013","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.expneurol.2017.08.014_bb0490","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0002-9440(10)65507-1","article-title":"Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A\/p16 inactivation","volume":"155","author":"Nielsen","year":"1999","journal-title":"Am. J. Pathol."},{"issue":"7","key":"10.1016\/j.expneurol.2017.08.014_bb0495","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1158\/2159-8290.CD-13-0245","article-title":"ERK pathway inhibitors: how low should we go?","volume":"3","author":"Nissan","year":"2013","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.expneurol.2017.08.014_bb0500","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1158\/0008-5472.CAN-13-2625","article-title":"Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence","volume":"74","author":"Nissan","year":"2014","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.expneurol.2017.08.014_bb0505","doi-asserted-by":"crossref","first-page":"524","DOI":"10.2353\/jmoldx.2009.090064","article-title":"Detection and characterization of NF1 microdeletions by custom high resolution array CGH","volume":"11","author":"Pasmant","year":"2009","journal-title":"J. Mol. Diagn."},{"issue":"6","key":"10.1016\/j.expneurol.2017.08.014_bb0510","doi-asserted-by":"crossref","first-page":"E1506","DOI":"10.1002\/humu.21271","article-title":"NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype","volume":"31","author":"Pasmant","year":"2010","journal-title":"Hum. Mutat."},{"issue":"3","key":"10.1016\/j.expneurol.2017.08.014_bb0515","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s11060-013-1185-4","article-title":"Relevance of MPNST cell lines as models for NF1 associated-tumors","volume":"114","author":"Pasmant","year":"2013","journal-title":"J. Neuro-Oncol."},{"issue":"18","key":"10.1016\/j.expneurol.2017.08.014_bb0520","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1158\/1078-0432.CCR-12-1072","article-title":"Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target","volume":"18","author":"Patel","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.expneurol.2017.08.014_bb0525","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.celrep.2013.12.001","article-title":"BET bromodomain inhibition triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors through Bim induction","volume":"6","author":"Patel","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.expneurol.2017.08.014_bb0530","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ebiom.2016.06.007","article-title":"An ShRNA screen identifies MEIS1 as a driver of malignant peripheral nerve sheath tumors","volume":"9","author":"Patel","year":"2016","journal-title":"EBioMedicine"},{"issue":"11","key":"10.1016\/j.expneurol.2017.08.014_bb0535","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/labinvest.3700675","article-title":"An orthotopic xenograft model of intraneural NF1 MPNST suggests a potential association between steroid hormones and tumor cell proliferation","volume":"87","author":"Perrin","year":"2007","journal-title":"Lab. Investig."},{"issue":"6","key":"10.1016\/j.expneurol.2017.08.014_bb0540","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1215\/15228517-2009-003","article-title":"PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor","volume":"11","author":"Perrone","year":"2009","journal-title":"Neuro-Oncology"},{"issue":"13","key":"10.1016\/j.expneurol.2017.08.014_bb0545","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1158\/1078-0432.CCR-09-3064","article-title":"Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response","volume":"16","author":"Pratilas","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.expneurol.2017.08.014_bb0550","doi-asserted-by":"crossref","first-page":"9375","DOI":"10.1158\/0008-5472.CAN-08-2223","article-title":"Genetic predictors of MEK dependence in non-small cell lung cancer","volume":"68","author":"Pratilas","year":"2008","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.expneurol.2017.08.014_bb0555","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/PAS.0000000000000564","article-title":"Loss of H3K27me3 expression is a highly sensitive marker for sporadic and radiation-induced MPNST","volume":"40","author":"Prieto-Granada","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"issue":"7","key":"10.1016\/j.expneurol.2017.08.014_bb0560","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1158\/1541-7786.MCR-14-0182","article-title":"STAT3 and HIF1alpha signaling drives oncogenic cellular phenotypes in malignant peripheral nerve sheath tumors","volume":"13","author":"Rad","year":"2015","journal-title":"Mol. Cancer Res."},{"issue":"13","key":"10.1016\/j.expneurol.2017.08.014_bb0565","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1158\/1078-0432.CCR-15-2377","article-title":"Clinical and molecular characteristics of NF1-mutant lung cancer","volume":"22","author":"Redig","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.expneurol.2017.08.014_bb0570","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/hmg\/9.7.1059","article-title":"Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1","volume":"9","author":"Rutkowski","year":"2000","journal-title":"Hum. Mol. Genet."},{"issue":"2","key":"10.1016\/j.expneurol.2017.08.014_bb0575","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1055-3207(03)00003-6","article-title":"Combined-modality treatment of localized soft tissue sarcomas of the extremities","volume":"12","author":"Scaife","year":"2003","journal-title":"Surg. Oncol. Clin. N. Am."},{"issue":"1","key":"10.1016\/j.expneurol.2017.08.014_bb0580","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/modpathol.2015.134","article-title":"Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics","volume":"29","author":"Schaefer","year":"2016","journal-title":"Mod. Pathol."},{"issue":"6","key":"10.1016\/j.expneurol.2017.08.014_bb0585","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/cncr.29858","article-title":"SARC009: phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma","volume":"122","author":"Schuetze","year":"2016","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.expneurol.2017.08.014_bb0590","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1086\/515504","article-title":"Confirmation of a double-hit model for the NF1 gene in benign neurofibromas","volume":"61","author":"Serra","year":"1997","journal-title":"Am. J. Hum. Genet."},{"issue":"3","key":"10.1016\/j.expneurol.2017.08.014_bb0595","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/his.12021","article-title":"BRAF V600E and KRAS G12S mutations in peripheral nerve sheath tumours","volume":"62","author":"Serrano","year":"2013","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.expneurol.2017.08.014_bb0600","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/sj.cdd.4402057","article-title":"The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways","volume":"14","author":"Shapira","year":"2007","journal-title":"Cell Death Differ."},{"issue":"39","key":"10.1016\/j.expneurol.2017.08.014_bb0605","doi-asserted-by":"crossref","first-page":"30740","DOI":"10.1074\/jbc.M001702200","article-title":"Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts","volume":"275","author":"Sherman","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"7074","key":"10.1016\/j.expneurol.2017.08.014_bb0610","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nature04304","article-title":"BRAF mutation predicts sensitivity to MEK inhibition","volume":"439","author":"Solit","year":"2006","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.expneurol.2017.08.014_bb0615","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s00432-010-0846-3","article-title":"Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings","volume":"136","author":"Spurlock","year":"2010","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.expneurol.2017.08.014_bb0620","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/modpathol.2012.242","article-title":"Expression profiling of 519 kinase genes in matched malignant peripheral nerve sheath tumor\/plexiform neurofibroma samples is discriminatory and identifies mitotic regulators BUB1B, PBK and NEK2 as overexpressed with transformation","volume":"26","author":"Stricker","year":"2013","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.expneurol.2017.08.014_bb0625","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4137\/TOG.S8830","article-title":"Oncogene mutation survey in MPNST cell lines enhances the dominant role of hyperactive Ras in NF1 associated pro-survival and malignancy","volume":"5","author":"Sun","year":"2012","journal-title":"Transl. Oncogenomics."},{"issue":"6","key":"10.1016\/j.expneurol.2017.08.014_bb0630","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/1541-7786.MCR-12-0593","article-title":"RAS\/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST","volume":"11","author":"Sun","year":"2013","journal-title":"Mol. Cancer Res."},{"issue":"5","key":"10.1016\/j.expneurol.2017.08.014_bb0635","first-page":"5113","article-title":"A neurogenic tumor containing a low-grade malignant peripheral nerve sheath tumor (MPNST) component with loss of p16 expression and homozygous deletion of CDKN2A\/p16: a case report showing progression from a neurofibroma to a high-grade MPNST","volume":"8","author":"Tajima","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"6","key":"10.1016\/j.expneurol.2017.08.014_bb0640","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrclinonc.2012.61","article-title":"Patient-derived tumour xenografts as models for oncology drug development","volume":"9","author":"Tentler","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.expneurol.2017.08.014_bb0645","article-title":"Orthotopic xenografting of human luciferase-tagged malignant peripheral nerve sheath tumor cells for in vivo testing of candidate therapeutic agents","volume":"49","author":"Turk","year":"2011","journal-title":"J. Vis. Exp."},{"issue":"24","key":"10.1016\/j.expneurol.2017.08.014_bb0650","doi-asserted-by":"crossref","first-page":"35753","DOI":"10.18632\/oncotarget.7099","article-title":"Dual mTORC1\/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells","volume":"7","author":"Varin","year":"2016","journal-title":"Oncotarget"},{"issue":"5447","key":"10.1016\/j.expneurol.2017.08.014_bb0655","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1126\/science.286.5447.2176","article-title":"Mouse tumor model for neurofibromatosis type 1","volume":"286","author":"Vogel","year":"1999","journal-title":"Science (New York, N.Y.)"},{"issue":"6","key":"10.1016\/j.expneurol.2017.08.014_bb0660","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1158\/2159-8290.CD-13-0081","article-title":"Canonical Wnt\/beta-catenin signaling drives human Schwann cell transformation, progression, and tumor maintenance","volume":"3","author":"Watson","year":"2013","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.expneurol.2017.08.014_bb0665","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.18632\/oncotarget.1609","article-title":"Co-targeting the MAPK and PI3K\/AKT\/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity","volume":"5","author":"Watson","year":"2014","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.expneurol.2017.08.014_bb0670","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1158\/2159-8290.CD-12-0470","article-title":"A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition","volume":"3","author":"Whittaker","year":"2013","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.expneurol.2017.08.014_bb0675","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s11912-009-0045-z","article-title":"Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors","volume":"11","author":"Widemann","year":"2009","journal-title":"Curr. Oncol. Rep."},{"issue":"3","key":"10.1016\/j.expneurol.2017.08.014_bb0680","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/ajmg.a.36312","article-title":"CTF meeting 2012: translation of the basic understanding of the biology and genetics of NF1, NF2, and Schwannomatosis toward the development of effective therapies","volume":"164A","author":"Widemann","year":"2014","journal-title":"Am. J. Med. Genet. A"},{"issue":"suppl; abstr 11053","key":"10.1016\/j.expneurol.2017.08.014_bb0685","article-title":"SARC016: phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST)","volume":"34","author":"Widemann","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.expneurol.2017.08.014_bb0690","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.107.135830","article-title":"Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin","volume":"326","author":"Wojtkowiak","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.expneurol.2017.08.014_bb0695","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/onc.2012.579","article-title":"EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors","volume":"33","author":"Wu","year":"2014","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.expneurol.2017.08.014_bb0700","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/onc.2011.250","article-title":"Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF","volume":"31","author":"Xing","year":"2012","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.expneurol.2017.08.014_bb0705","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11060-014-1422-5","article-title":"Preclinical evaluation of the combination of mTOR and proteasome inhibitors with radiotherapy in malignant peripheral nerve sheath tumors","volume":"118","author":"Yamashita","year":"2014","journal-title":"J. Neuro-Oncol."},{"issue":"11","key":"10.1016\/j.expneurol.2017.08.014_bb0710","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/ng.3116","article-title":"Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors","volume":"46","author":"Zhang","year":"2014","journal-title":"Nat. Genet."},{"issue":"11","key":"10.1016\/j.expneurol.2017.08.014_bb0715","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1002\/(SICI)1097-0142(19970601)79:11<2125::AID-CNCR9>3.0.CO;2-N","article-title":"Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population","volume":"79","author":"Zoller","year":"1997","journal-title":"Cancer"}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488617302194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488617302194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T18:35:02Z","timestamp":1602873302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488617302194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":143,"alternative-id":["S0014488617302194"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2017.08.014","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The promise of signal transduction in genetically driven sarcomas of the nerve","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2017.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}